From height to health: Largest global genetic study reveals hidden risks and benefits linked to stature

New genetic links have been discovered between genetically-predicted height and an individual’s likelihood of developing a range of diseases and conditions. These new data could help improve early diagnosis and risk monitoring for patients. 

An international team of researchers, led by Queen Mary University of London, used data from six cohorts of diverse ancestries, including European, African, East Asian, and Hispanic populations, to explore the links between genetically predicted height and various diseases. Applying a Phenome-Wide Association Study (PheWAS) method the researchers analysed each group both within and across different ancestries. PheWAS is a method that examines how a genetic score – in this case for height –is associated with a broad range of health conditions. Rather than focusing on a single disease, it scans numerous health outcomes to uncover unexpected connections between the genetically predicted trait and various diseases. 

The researchers looked at 1,768 traits from over 800,000 people with diverse ancestries and found 254 statistically significant associations between genetically predicted height and disease across ancestries. The strongest links seen were between greater height and conditions related to the circulatory system, the endocrine/metabolic system, and musculoskeletal categories. 

More specifically, the strongest association was observed between genetically predicted height and atrial fibrillation in the sex-combined across ancestries analysis. The study also revealed ancestry-specific and sex-specific associations. For example, increased genetically predicted height was associated with decreased risk of Hyperpotassemia in males but showed no association in females. 

Some signals were significant only in the European ancestry meta-analysis for males ​and not in the cross-ancestry meta-analysis. For instance, increased genetically predicted height was associated with a decreased risk of anxiety disorders and post-traumatic stress disorder in males. 

One significant association was identified in the female-only meta-PheWAS but was not observed in the sex-combined meta-PheWAS: benign neoplasm of other parts of the digestive system. 

Dr Areti Papadopoulou, Postdoctoral Research Associate at the Medical Research Council Biostatistics Unit and first author, said: "Our study explored disease related outcomes in up to 840,000 individuals of European, African, East Asian and Hispanic population groups with genetically predicted height. We report associations with a series of disorders, involving mental disorders and the endocrine system, that have not been previously associated with genetically 
predicted height." 

Dr Eirini Marouli, last author and Associate Professor in Computational Biology at Queen Mary University of London, said: “Our study reveals significant links between genetically predicted height and various health conditions, providing new perspectives on disease risk. As a complex trait, height's associations with disease offer valuable insights into underlying biological mechanisms.  By analysing genetic data across diverse ancestries and incorporating sex-specific analyses, we have identified associations that could improve early diagnosis and patient care. This research underscores the importance of inclusive genetic studies, advancing our understanding of health across populations and ensuring that scientific progress benefits everyone."  

ENDS  

NOTES TO EDITORS  

Contact  

Sophia Prout   

Faculty Communications Manager – Medicine and Dentistry   

Queen Mary University of London   

Email: s.prout@qmul.ac.uk or press@qmul.ac.uk   

Paper details:    

A. Papadopoulou, et al. “Insights from the largest diverse ancestry sex-specific disease map for genetically predicted height.” Published in npj Genomic Medicine.  

DOI: l object identifier (DOI) number: 10.1038/s41525-025-00464-w 
Available at: https://www.nature.com/articles/s41525-025-00464-w.  

A copy of the paper is available upon request.  

Conflicts of interest:  The authors declare no competing interests. 

 Funded by:  National Institute for Health and Care Research Barts Biomedical Research Centre (NIHR203330) 

About Queen Mary    

www.qmul.ac.uk      

At Queen Mary University of London, we believe that a diversity of ideas helps us achieve the previously unthinkable.   

Throughout our history, we’ve fostered social justice and improved lives through academic excellence. And we continue to live and breathe this spirit today, not because it’s simply ‘the right thing to do’ but for what it helps us achieve and the intellectual brilliance it delivers.     

Our reformer heritage informs our conviction that great ideas can and should come from anywhere. It’s an approach that has brought results across the globe, from the communities of east London to the favelas of Rio de Janeiro.     

We continue to embrace diversity of thought and opinion in everything we do, in the belief that when views collide, disciplines interact, and perspectives intersect, truly original thought takes form.    

About NIHR 

The mission of the National Institute for Health and Care Research (NIHR) is to improve the health and wealth of the nation through research. We do this by: 

• Funding high quality, timely research that benefits the NHS, public health and social care; 

• Investing in world-class expertise, facilities and a skilled delivery workforce to translate discoveries into improved treatments and services; 

• Partnering with patients, service users, carers and communities, improving the relevance, quality and impact of our research; 

• Attracting, training and supporting the best researchers to tackle complex health and social care challenges; 

• Collaborating with other public funders, charities and industry to help shape a cohesive and globally competitive research system; 

• Funding applied global health research and training to meet the needs of the poorest people in low and middle income countries. 

NIHR is funded by the Department of Health and Social Care. Its work in low and middle income countries is principally funded through UK international development funding from the UK government.